Liver Specific Serum Micro RNA122 as a Prognostic Marker in Egyptian Patients with Liver Cirrhosis
Journal Title: Archives of Hepatitis Research - Year 2017, Vol 3, Issue 1
Abstract
Introduction: Recent research has shown that microRNAs (miRNA) are emerging as important regulators of cellular differentiation. The miR-122 accounts for approximately 70% of all miRNAs in the liver so its presence in the serum is highly indicative of liver processes. Aim of the work and methods: was to study the role of miR-122 as a prognostic new marker in patients with liver cirrhosis. MiR-122 was detected by quantitative real-time reverse transcription (RT)-PCR technique. Eighty patients with liver cirrhosis were included in our study, we divided them into 4 equal groups according to the complications of liver cirrhosis (1-compensated cirrhotics, 2- cirrhotics with ascites, 3-spontaneous bacterial peritonitis (SBP), and 4- hepatorenal syndrome (HRS) group) to evaluate if the serum level of miR-122 might be a suitable parameter for assessment of disease severity and prognosis in such patients.
Authors and Affiliations
Amin Mona A, Fawzi Mai, Sabri Dina, Sedrak Heba, Mausa Shrouk, El-Saadi Abdelaziz
Keywords
Related Articles
- EP ID EP559374
- DOI 10.17352/ahr.000008
- Views 49
- Downloads 0
The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis
Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in d...
Sarcoidosis-Lymphoma Syndrome presenting by severe Cholestatic Hepatitis
Severe cholestatic hepatitis is an uncommon presentation of either sarcoidosis or Hodgkin lymphoma. Sarcoidosis lymphoma syndrome is a rare disorder with sarcoidosis heralding the onset of lymphoma. Here we report a case...
Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to...
Non-Alcoholic Fatty Liver Disease Frequency among Healthy Blood Donors in the West of Iran
Objectives: To investigate the prevalence of NAFLD as well as the determination of associated metabolic abnormalities in Iranian blood donors. The aim of this study was to review cases of non-alcoholic fatty liver diseas...
Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. The spectrum of th...